Tags

Type your tag names separated by a space and hit enter

Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years.
Acta Orthop 2011; 82(2):211-6AO

Abstract

BACKGROUND AND PURPOSE

The Scandinavian Sarcoma Group (SSG) XIV protocol is based on experience from previous SSG trials and other osteosarcoma intergroup trials, and has been considered the best standard of care for patients with extremity localized, non-metastatic osteosarcoma. We analyzed the outcome in 63 consecutive patients. Patients and methods From 2001 through 2005, 63 patients recruited from centers in Sweden, Norway, and Finland were included. They received preoperative chemotherapy consisting of 2 cycles of paired methotrexate (12 g/m²), cisplatin (90 mg/m²), and doxorubicin (75 mg/m²). 3 cycles were administered postoperatively, and poor histological responders were given 3 additional cycles of ifosfamide (10-12 g/m²) as a salvage strategy.

RESULTS

With a median follow-up of 77 months for survivors, the estimated metastasis-free and sarcoma-related survival at 5 years was 70% and 76%, respectively. 53 patients were treated with limb salvage surgery or rotationplasty and 2 patients experienced a local recurrence. 3 toxic deaths were recorded, all related to acute toxicity from chemotherapy. The 5-year metastasis-free survival of poor histological responders receiving add-on treatment with ifosfamide was 47%, as compared to 89% for good histological responders.

INTERPRETATION

Outcome from the SSG XIV protocol compares favorably with the results of previous SSG trials and other published osteosarcoma trials. However, salvage therapy given to poor responders did not improve outcome to a similar degree as for good responders. In a multi-institutional setting, more than four-fifths of the patients were operated with limb salvage surgery or rotationplasty, with few local recurrences.

Authors+Show Affiliations

Division of Surgery and Cancer Medicine, Oslo University Hospital, Norway. sigbjorn.smeland@medisin.uio.noNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21434784

Citation

Smeland, Sigbjørn, et al. "Results of the Scandinavian Sarcoma Group XIV Protocol for Classical Osteosarcoma: 63 Patients With a Minimum Follow-up of 4 Years." Acta Orthopaedica, vol. 82, no. 2, 2011, pp. 211-6.
Smeland S, Bruland OS, Hjorth L, et al. Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years. Acta Orthop. 2011;82(2):211-6.
Smeland, S., Bruland, O. S., Hjorth, L., Brosjö, O., Bjerkehagen, B., Osterlundh, G., ... Alvegaard, T. A. (2011). Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years. Acta Orthopaedica, 82(2), pp. 211-6. doi:10.3109/17453674.2011.566141.
Smeland S, et al. Results of the Scandinavian Sarcoma Group XIV Protocol for Classical Osteosarcoma: 63 Patients With a Minimum Follow-up of 4 Years. Acta Orthop. 2011;82(2):211-6. PubMed PMID: 21434784.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years. AU - Smeland,Sigbjørn, AU - Bruland,Oyvind S, AU - Hjorth,Lars, AU - Brosjö,Otte, AU - Bjerkehagen,Bodil, AU - Osterlundh,Gustaf, AU - Jakobson,Ake, AU - Hall,Kirsten Sundby, AU - Monge,Odd R, AU - Björk,Olle, AU - Alvegaard,Thor A, Y1 - 2011/03/24/ PY - 2011/3/26/entrez PY - 2011/3/26/pubmed PY - 2011/5/20/medline SP - 211 EP - 6 JF - Acta orthopaedica JO - Acta Orthop VL - 82 IS - 2 N2 - BACKGROUND AND PURPOSE: The Scandinavian Sarcoma Group (SSG) XIV protocol is based on experience from previous SSG trials and other osteosarcoma intergroup trials, and has been considered the best standard of care for patients with extremity localized, non-metastatic osteosarcoma. We analyzed the outcome in 63 consecutive patients. Patients and methods From 2001 through 2005, 63 patients recruited from centers in Sweden, Norway, and Finland were included. They received preoperative chemotherapy consisting of 2 cycles of paired methotrexate (12 g/m²), cisplatin (90 mg/m²), and doxorubicin (75 mg/m²). 3 cycles were administered postoperatively, and poor histological responders were given 3 additional cycles of ifosfamide (10-12 g/m²) as a salvage strategy. RESULTS: With a median follow-up of 77 months for survivors, the estimated metastasis-free and sarcoma-related survival at 5 years was 70% and 76%, respectively. 53 patients were treated with limb salvage surgery or rotationplasty and 2 patients experienced a local recurrence. 3 toxic deaths were recorded, all related to acute toxicity from chemotherapy. The 5-year metastasis-free survival of poor histological responders receiving add-on treatment with ifosfamide was 47%, as compared to 89% for good histological responders. INTERPRETATION: Outcome from the SSG XIV protocol compares favorably with the results of previous SSG trials and other published osteosarcoma trials. However, salvage therapy given to poor responders did not improve outcome to a similar degree as for good responders. In a multi-institutional setting, more than four-fifths of the patients were operated with limb salvage surgery or rotationplasty, with few local recurrences. SN - 1745-3682 UR - https://www.unboundmedicine.com/medline/citation/21434784/Results_of_the_Scandinavian_Sarcoma_Group_XIV_protocol_for_classical_osteosarcoma:_63_patients_with_a_minimum_follow_up_of_4_years_ L2 - http://www.tandfonline.com/doi/full/10.3109/17453674.2011.566141 DB - PRIME DP - Unbound Medicine ER -